中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.022 seconds)

    DUAL SPECIFICITY POLYPEPTIDE MOLECULE
    11.
    发明申请
    DUAL SPECIFICITY POLYPEPTIDE MOLECULE 审中-公开

    公开(公告)号：US20190016804A1

    公开(公告)日：2019-01-17

    申请号：US16035429

    申请日：2018-07-13

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Martin HOFMANN ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER

    IPC: C07K16/28 ,  C07K16/10

    Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    15.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230091330A1

    公开(公告)日：2023-03-23

    申请号：US17934303

    申请日：2022-09-22

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/28 ,  C07K16/46

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    BMA031 ANTIGEN BINDING POLYPEPTIDES
    17.
    发明申请
    BMA031 ANTIGEN BINDING POLYPEPTIDES 有权

    公开(公告)号：US20250051445A1

    公开(公告)日：2025-02-13

    申请号：US18929969

    申请日：2024-10-29

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sebastian BUNK ,  Felix UNVERDORBEN ,  Martin HOFMANN

    IPC: C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783

    Abstract: Antigen binding polypeptide specifically binding to a α/β T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the α/β TCR/CD3 complex.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    19.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230132241A1

    公开(公告)日：2023-04-27

    申请号：US17793237

    申请日：2020-01-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Dominik MAURER ,  Gabriele PSZOLLA ,  Frank SCHWOEBEL ,  Felix UNVERDORBEN ,  Claudia WAGNER ,  Sara YOUSEF

    IPC: C07K16/30 ,  C12N15/63 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    20.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20220372165A1

    公开(公告)日：2022-11-24

    申请号：US17736882

    申请日：2022-05-04

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Gabriele PSZOLLA ,  Martin HOFMANN ,  Meike HUTT ,  Sebastian BUNK ,  Felix UNVERDORBEN ,  Frank SCHWOEBEL ,  Dominik MAURER ,  Maike JAWORSKI ,  Claudia WAGNER ,  Florian SCHWOERER ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K16/46 ,  C07K16/28

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Patent Agency Ranking